Veracyte develops molecular diagnostic tests that assess the unique biology of each patient's tumour, helping clinicians make more informed decisions for thyroid, prostate, breast, bladder, and lung cancer. These genomic tests analyse biological markers to answer critical questions, such as whether a patient can avoid surgery, delay treatment, or receive personalised therapy. By transforming uncertainty into actionable insights, Veracyte empowers clinicians to guide patients toward more personalised care. With over 800,000 patients benefiting from these tests and more than 600 peer-reviewed publications validating their clinical utility, Veracyte serves as a trusted partner in advancing precision oncology.
755
Team Members
2006
Founded
Diagnostics
Sector
Hybrid
Work Environment
A world where every cancer patient receives care guided by the precise molecular insights of their unique tumour biology, eliminating uncertainty and enabling confident decisions that improve outcomes and quality of life.
At Veracyte, our mission is to transform cancer care for patients all over the world by empowering clinicians with high-value molecular insights that guide and assure patients at pivotal moments in their diagnosis and treatment journey.
Loading open positions…
Join our team! Explore current opportunities at Veracyte.